Navigation Links
Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
Date:5/20/2010

"xn-person">Andrew R. Haas, M.D., Ph.D., Hospital of the University of Pennsylvania, and investigator on JX-594 Phase 1 trial.

This open-label, dose-escalation study was completed at four sites in the United States and Canada.  A total of 23 patients with solid tumors refractory to standard therapy were enrolled.  Patients received a single treatment at one of five dose levels, with follow-up at periodic intervals.  Six out of eight patients in the higher-dose cohorts evaluable to date (cohorts 3, 4, 5) exhibited disease control as defined by stable disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria and/or Choi (necrotic) response.  Two out of six patients in the low dose cohorts exhibited disease control (RECIST stable disease) but no responses.  The primary endpoints of the trial included safety and determination of the maximum tolerated dose given through intravenous administration.  No serious adverse events related to JX-594 therapy were reported and no dose-limiting toxicities were reported.  A biomarker analysis further strengthened the finding of dose-dependent replication in tumors following IV administration.

About JX-594

JX-594, currently in Phase 2 clinical trials for liver cancer, is a cancer biotherapeutic product from a proprietary breakthrough class of targeted and armed oncolytic and immunotherapeutic poxviruses.  Tumor destruction and safety was shown in patients with diverse cancer types in three Phase 1 trials; treated patients were end-stage and had no effective therapies available.  JX-594 multiplies selectively within cancer cells, leading to their destruction.  These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
3. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
4. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
5. Jennerex Closes $5 Million First Tranche of Series C Financing
6. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 Protiviti ( www.protiviti.com ), ... of the Governance Portal , designed to increase ... compliance (GRC) tasks across multiple business units and projects. ... help customers better align their controls with the COSO ... ) requirements. In response to client feedback, Protiviti has ...
(Date:2/26/2015)... On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... -- BioEnterprise today announced that Northeast Ohio ... billion in growth funding during the past 13 years.  ... state – including the Ohio Third Frontier - and ... been raised in the past five years. ... BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Innovation ... are emerging from unexpected parts of the world ... From agriculture to manufacturing to health care, ... and environmental realities and socio-political trends shake the ... the key ingredient for CEOs to survive the ...
Breaking Biology Technology:Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 2Protiviti Governance Portal Helps Companies Drive Governance, Risk and Compliance Productivity Across Multiple Business Units 3Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... to Phlo,Corporation,s ("Phlo"") (OTC: PHLC) press release of December ... York City Account,Base," an affiliate of Phlo (the "Company") ... City has sold and delivered,AQISS(TM) to the following initial ... such roll out. AQISS(TM) is currently available for sale ...
... Denmark, Feb. 11 Santaris Pharma, the,Danish biopharmaceutical ... Keith McCullagh, President and Chief Executive,Officer, will be ... goals for,2008 at the Biotechnology Industry Organisation,s 10th ... Monday February 11th at 12:30 pm,US Eastern Standard ...
... Va., Feb. 11 A report released,today, commissioned by ... of approximately $378 billion over the next 20 years ... The econometric study by economist Dr. Robert J. ... found that "...generic,versions of the top 12 categories of ...
Cached Biology Technology:Phlo Affiliate Reports Progress in New York City Metropolitan Area Roll-Out 2Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008 2Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 2Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 3Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 4Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics 5
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and Voice Biometrics ... Biometrics. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , Middle ... Latin America . Annual estimates and forecasts are provided ... is provided for these markets. Market data and analytics are derived ...
(Date:2/19/2015)... DUBLIN , Feb .19, 2015 Research ... announced the addition of the "Military Electro-Optical ... by Sensor Technology, by Platform - Forecast to ... The military electro-optical/infrared systems market is expected ... a CAGR of 7.71%. This report ...
(Date:2/12/2015)... 12, 2015   MedNet Solutions , a ... study management systems, has recently bolstered its ... iMedNet as the eClinical ... and healthcare consultants.  Building on the Program,s existing ... and numerous co-marketing opportunities), MedNet,s new and improved ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... , This release is available in French ... that brains are sensitive to the quality of child care, ... Lupien and her colleagues from the University of Montreal published ... Sciences . The scientists worked with ten year old children ...
... roads as weed highways, and chemical warfare between alien and native ... in NeoBiota a new open-access, peer-reviewed, rapid ... Pensoft Publishers continuing the former NeoBiota Proceedings ... Khn from the Helmholtz Centre for Environmental Research ...
... Center,s Departments of Orthopaedic Surgery and Radiology found that ... changes in joint cartilage microstructure and provide physicians ... osteoarthritis (OA). By using these techniques during patient exams ... of the disease from eventual joint reconstruction to long-term ...
Cached Biology News:Children of depressed mothers have a different brain 2Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 2Open minded and open access: NeoBiota, a new publishing platform for invasion biologists 3NYU Langone experts find MRI techniques can detect early osteoarthritis 2
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Request Info...
Biology Products: